VBI VACCINES INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.574 USD | -4.24% |
|
-9.42% | -2.30% |
| Apr. 16 | VBI Vaccines Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Apr. 15 | North American Morning Briefing : Stock Futures -2- | DJ |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 246 | 665.6 | 602.1 | 101 | 13.92 | 16.32 | - | - |
| Enterprise Value (EV) 1 | 246 | 665.6 | 602.1 | 101 | 13.92 | 16.32 | 16.32 | 16.32 |
| P/E ratio | -3 x | -13.1 x | -8.67 x | -0.89 x | -0.1 x | -0.41 x | -1.13 x | -2.3 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 111 x | 627 x | 954 x | 93.3 x | 1.6 x | 1.13 x | 0.48 x | 0.28 x |
| EV / Revenue | 111 x | 627 x | 954 x | 93.3 x | 1.6 x | 1.13 x | 0.48 x | 0.28 x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / FCF | - | - | - | -1.29 x | - | -0.44 x | -0.95 x | -1.67 x |
| FCF Yield | - | - | - | -77.3% | - | -227% | -105% | -59.8% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 5,942 | 8,068 | 8,577 | 8,609 | 23,688 | 28,432 | - | - |
| Reference price 2 | 41.40 | 82.50 | 70.20 | 11.73 | 0.5875 | 0.5740 | 0.5740 | 0.5740 |
| Announcement Date | 3/5/20 | 3/2/21 | 3/7/22 | 3/13/23 | 4/16/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2.221 | 1.061 | 0.631 | 1.082 | 8.682 | 14.48 | 34.12 | 58.84 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -52.4 | -43.62 | -68.03 | -81.82 | -79.91 | -37.51 | -20.02 | -15.3 |
| Operating Margin | -2,359.25% | -4,110.93% | -10,781.62% | -7,561.92% | -920.42% | -259.02% | -58.66% | -26% |
| Earnings before Tax (EBT) 1 | -54.81 | -46.23 | -69.75 | -113.3 | -92.84 | -42.81 | -25.13 | -14.27 |
| Net income 1 | -54.81 | -46.23 | -69.75 | -113.3 | -93.84 | -42.81 | -25.13 | -14.27 |
| Net margin | -2,467.94% | -4,357.21% | -11,054.36% | -10,471.63% | -1,080.87% | -295.62% | -73.65% | -24.26% |
| EPS 2 | -13.80 | -6.300 | -8.100 | -13.20 | -6.030 | -1.390 | -0.5100 | -0.2500 |
| Free Cash Flow 1 | - | - | - | -78.04 | - | -37.03 | -17.18 | -9.761 |
| FCF margin | - | - | - | -7,212.48% | - | -255.73% | -50.36% | -16.59% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/5/20 | 3/2/21 | 3/7/22 | 3/13/23 | 4/16/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.107 | 0.081 | 0.126 | 0.346 | 0.317 | 0.293 | 0.485 | 0.72 | 6.624 | 0.853 | 2.852 | 3.189 | 3.877 | 4.564 | 6.549 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -15.02 | -20.87 | -15.92 | -22.9 | -21.56 | -21.44 | -19.51 | -16.97 | -6.469 | -13.36 | -10.27 | -9.847 | -9.077 | -8.313 | -6.586 |
| Operating Margin | -14,041.12% | -25,767.9% | -12,634.92% | -6,619.36% | -6,800.63% | -7,317.06% | -4,022.47% | -2,357.22% | -97.66% | -1,566.71% | -360.1% | -308.78% | -234.12% | -182.14% | -100.56% |
| Earnings before Tax (EBT) 1 | -15.85 | -18.78 | -21.25 | -45.7 | -25.21 | -21.14 | -27.75 | -44.63 | -20.44 | -0.013 | -11.42 | -11.18 | -10.49 | -9.721 | -7.949 |
| Net income 1 | -15.85 | -18.78 | -21.25 | -45.7 | -25.21 | -21.14 | -27.75 | -44.63 | -21.31 | -0.156 | -11.42 | -11.18 | -10.49 | -9.721 | -7.949 |
| Net margin | -14,810.28% | -23,188.89% | -16,868.25% | -13,207.8% | -7,952.37% | -7,215.36% | -5,721.86% | -6,198.33% | -321.65% | -18.29% | -400.35% | -350.61% | -270.54% | -212.99% | -121.38% |
| EPS 2 | -1.800 | -2.100 | -2.400 | -5.400 | -3.000 | -2.400 | -3.220 | -5.050 | -1.010 | - | -0.5300 | -0.4700 | -0.3100 | -0.2200 | -0.1800 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/8/21 | 3/7/22 | 5/9/22 | 8/8/22 | 11/10/22 | 3/13/23 | 5/15/23 | 8/14/23 | 11/14/23 | 4/16/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | -78 | - | -37 | -17.2 | -9.76 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 3.67 | 1 | 2 | 4.34 | - | 0.7 | 0.73 | 0.62 |
| Capex / Sales | 165.38% | 94.25% | 316.16% | 401.48% | - | 4.81% | 2.12% | 1.05% |
| Announcement Date | 3/5/20 | 3/2/21 | 3/7/22 | 3/13/23 | 4/16/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.574
USD
Average target price
5
USD
Spread / Average Target
+771.08%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -2.30% | 16.32M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- VBIV Stock
- Financials VBI Vaccines Inc.
